- ►diabetesjournals.org KM Rave, L Nosek, A de la Peña, M Seger, … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—HIIP demonstrated a similar rapid onset but an extended time exposure
and a prolonged duration of effect (late t 50% 412 vs. 236 min, P < 0.001)
compared with SC lispro. The HIIP versus SC lispro doses of 2.6 mg vs. 6 ... Cited by 61 - Related articles - BL Direct - All 5 versions
TK Mandal - American Journal of Health-System Pharmacy, 2005 - ASHP Purpose. Pharmacokinetic and safety data related to the use of inhaled insulin
for the management of diabetes mellitus are dis- cussed. The various pulmonary
insulin de- livery systems under development are also reviewed. Summary. ... Cited by 43 - Related articles - BL Direct - All 9 versions
PS Odegard, KL Capoccia - The Annals of pharmacotherapy, 2005 - Harvey Whitney Books Diabetes mellitus affects >18 million Americans.1 Type 1 diabetes is diagnosed
most often in children, adoles- cents, or young adults and is characterized by
failure of the pancreatic islet cells to produce insulin.2 Individuals with ... Cited by 42 - Related articles - All 4 versions
MJ Telko, AJ Hickey - Respiratory care, 2005 - ncbi.nlm.nih.gov A drug product combines pharmacologic activity with pharmaceutical properties.
Desirable performance characteristics are physical and chemical stability, ease
of processing, accurate and reproducible delivery to the target organ, and ... Cited by 40 - Related articles - BL Direct - All 4 versions
ES Khafagy, M Morishita, Y Onuki, K … - Advanced Drug Delivery Reviews, 2007 - Elsevier The quest to eliminate the needle from insulin delivery and to replace it with
non- or less-invasive alternative routes has driven rigorous pharmaceutical
research to replace the injectable forms of insulin. Recently, various ... Cited by 32 - Related articles - All 3 versions
JD Brain - DIABETES OBESITY AND METABOLISM, 2005 - interscience.wiley.com Clinical studies of inhaled insulins suggest that pulmonary delivery is well
tolerated, with a level of safety comparable to that of subcutaneous (SC)
insulin. Questions about the safety of Exubera ® focus primarily on the ... Cited by 27 - Related articles - BL Direct - All 5 versions
- ►ntu.edu.tw [PDF] S Sajeesh, CP Sharma - International journal of pharmaceutics, 2006 - Elsevier Present investigation was aimed at developing an oral insulin delivery system
based on hydroxypropyl β cyclodextrin–insulin (HPβCD–I) complex
encapsulated polymethacrylic acid-chitosan-polyether (polyethylene glycol- ... Cited by 26 - Related articles - All 5 versions
G Walsh - Applied microbiology and biotechnology, 2005 - Springer Abstract Biotechnological innovations over the past 25 years have underpinned
the rapid development of a thriving biopharmaceutical sector. Therapeutic
insulin remains one of the most commonly used products of pharmaceutical ... Cited by 25 - Related articles - All 6 versions
CL Nykiforuk, JG Boothe, EW Murray, RG … - Plant Biotechnology Journal, 2006 - sembiosys.com Cory L. Nykiforuk1, Joseph G. Boothe1, Elizabeth W. Murray1, Richard G. Keon1,
H. Joseph Goren2, Nancy A. Markley1 and Maurice M. Moloney1,* ... 1SemBioSys
Genetics Inc, 110, 2985-23 Ave NE, Calgary, AB, T1Y 7L3, Canada 2Department ... Cited by 20 - Related articles - View as HTML - BL Direct - All 8 versions
LR Brown - edd, 2005 - informahealthcare.com The discovery of insulin in 1922 marked the beginning of research and devel-
opment to improve the means of delivering protein therapeutics to patients. From
that period forward, investigators have contemplated every possible route ... Cited by 19 - Related articles - BL Direct - All 4 versions
